Prognostic markers in triple‐negative breast cancer

Triple‐negative breast cancer (estrogen receptor‐negative, progesterone receptor‐negative, and HER2‐negative) is a high risk breast cancer that lacks the benefit of specific therapy that targets these proteins.

[1]  D. Cosgrove The breast , 1999, European Radiology.

[2]  François Vaillant,et al.  Steroid hormone receptor status of mouse mammary stem cells. , 2006, Journal of the National Cancer Institute.

[3]  S. Schnitt,et al.  Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer , 2006, Modern Pathology.

[4]  M. Hung,et al.  Dysregulation of cellular signaling by HER2/neu in breast cancer. , 2003, Seminars in oncology.

[5]  G. Ball,et al.  High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.

[6]  C. Isaacs,et al.  Prognostic Factors in Breast Cancer: Current and New Predictors of Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.

[7]  Shousha,et al.  Adenoid cystic carcinoma of the breast: a tumour commonly devoid of oestrogen receptors and related proteins , 1999, Histopathology.

[8]  S. Shousha,et al.  Morphologic spectrum of estrogen receptor-negative breast carcinoma. , 2002, Archives of pathology & laboratory medicine.

[9]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Ian O Ellis,et al.  Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis , 2005, Modern Pathology.

[11]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[12]  B. Moon,et al.  Secretory carcinoma of the breast , 2003, Journal of clinical ultrasound : JCU.

[13]  J. Robertson,et al.  Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation , 2006, The Journal of pathology.

[14]  Paul E Swanson,et al.  Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. , 2003, American journal of clinical pathology.

[15]  A. Bednarek,et al.  Prognostic Relevance of Basal Cytokeratin Expression in Operable Breast Cancer , 2006, Oncology.

[16]  S. Takekoshi,et al.  Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. , 2005, Oncology reports.

[17]  I. Ellis,et al.  Expression of luminal and basal cytokeratins in human breast carcinoma , 2004, The Journal of pathology.

[18]  D. Fouskakis,et al.  Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients. , 2004, Anticancer research.

[19]  I. Ellis,et al.  The prognosis of small primary breast cancers. , 1999, European journal of cancer.

[20]  C. Benz,et al.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies , 2006, Molecular Cancer.

[21]  I. Ellis,et al.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma , 2004, British Journal of Cancer.

[22]  F. Melsen,et al.  Prognostic comparison of three classifications for medullary carcinomas of the breast , 1997, Histopathology.

[23]  M. Piccart,et al.  An overview of HER2. , 2001, Seminars in oncology.

[24]  J. Nesland,et al.  The prognostic value of p53 and c‐erb b‐2 immunostaining is overrated for patients with lymph node negative breast carcinoma , 2000, Cancer.

[25]  W. Bezwoda C-erb-B2 expression and response to treatment in metastatic breast cancer , 2000, Medical oncology.

[26]  R. Tibshirani,et al.  Copyright © American Society for Investigative Pathology Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome , 2022 .

[27]  W D Dupont,et al.  Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading , 1984, Cancer.

[28]  Qifeng Yang,et al.  Predictive and prognostic markers for invasive breast cancer , 2002, Pathology international.

[29]  M. Kimmel,et al.  Estrogen Receptor Protein of Breast Cancer in Patients With Positive Nodes: High Recurrence Rates in the Postmenopausal Estrogen Receptor—Negative Group , 1987 .

[30]  D. Rimm,et al.  Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.

[31]  A. Dursun,et al.  The Prognostic Value of p53 and c-erbB-2 Expression, Proliferative Activity and Angiogenesis in Node-Negative Breast Carcinoma , 2005, Tumori.

[32]  I. Ellis,et al.  The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.

[33]  B. Asselain,et al.  Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. , 1996, British Journal of Cancer.

[34]  G. Moreno-Bueno,et al.  The Prognostic Significance of P-Cadherin in Infiltrating Ductal Breast Carcinoma , 2001, Modern Pathology.

[35]  Ash A. Alizadeh,et al.  Towards a novel classification of human malignancies based on gene expression patterns , 2001, The Journal of pathology.

[36]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[39]  L. Hartmann,et al.  Prognostic value of c‐erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol , 1994, Cancer.

[40]  T. H. van der Kwast,et al.  The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. , 1996, European journal of cancer.

[41]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[42]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[43]  M. Piccart,et al.  HER2/neu as a predictive factor in breast cancer. , 2001, Clinical breast cancer.

[44]  R. Blamey,et al.  E-cadherin as a prognostic indicator in primary breast cancer , 2001, British Journal of Cancer.

[45]  Donald E. Henson,et al.  Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .

[46]  M. Dowsett,et al.  Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  R. Moll,et al.  Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas , 1998, Virchows Archiv.